參考文獻 |
張亭棟,李元善 1984. 癌靈1號治療急性粒細胞白血病臨床分析及實驗研究。 中西醫結合雜誌.1984, 4(1):19-20.
黃世林等 1995. 復方青黛片為主治療急性早幼粒細胞白血病的臨床研究。 中華血液學雜誌1995, 16(1):26-8.
張鵬等1996. 三氧化二砷注射液治療72例急性早幼粒細胞白血病。Chin J Hematol, 2:58.
Aposhian, H.V. 1989. Biochemical toxicology of arsenic. Rev. Biochem. Toxicol. 10:265-299.
Avvisati, G., J.W. Cate, A. Sturk, R. Lamping, M.G. Petti, and I.F. Mandell. 1988. Acquired alpha-2-antiplasmin deficiency in acute promyelocytic leukaemia. Br. J. Haematol. 70:43-48.
Berolero, F., G. Pozzi, E. Sabbioni, and U. Saffiotti. 1987. Cellular uptake and metabolic reduction of pentavalent to trivalent arsenic as determinants of cytotoxicity and morphological transformation. Carcinogenesis. 8:803-808.
Borrow, J., A.D. Goddard, D. Sheer, and E. Solomon. 1990. Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science. 249:1577-1580.
Brower, M.S., and P.C. Harpel. 1982. Proteolytic cleavage and inactivation of alpha-2-plasmin inhibitor and C1 inactivator by human polymorphonuclear leukocyte elastase. J. Biol. Chem. 257:9849-9854.
Buchet, J.P., and R. Lauwerys. 1985. Study of inorganic arsenic methylation by rat liver in vitro: relevance for the interpretation of observation in man. Arch. Toxicol. 57:125-129.
Castaigne, S., C. Chomienne, and M.T. Daniel. 1990. Retinoic acids in the treatment of acute promyelocytic leukemia. Nouv. Rev. Fr. Hematol. 32:36-38.
Chae, H.Z., H.J. Kim, S.W. Kang, and S.G. Rhee. 1999. Characterization of three isoforms of mammalian peroxiredoxin that reduce peroxides in the presence of thioredoxin. Diabetes. Res. Clin. Pract. 45:101-112.
Chae, H.Z., I.H. Kim, K. Kim, and S.G. Rhee. 1993. Cloning, sequencing, and mutation of thiol-specific antioxidant gene of Saccharomyces cerevisiae. J, Biol. Chem. 268:16815-16821.
Chen, C.J., Y.C. Chuang, T.M. Lin, and H.Y. Wu. 1985. Malignant neoplasms among residents of a blackfoot diease-endemic area in Taiwan: hight-arsenic artesian well water and cancers,. Cancer Res. 45:5895-5899.
Chen, C.J., Y.M. Hsueh, M.S. Lai, M.P. Shyu, S.Y. Chen, M.M. Wu, T.L. Kuo, and T.Y. Tai. 1995. Increased prevalence of hypertension and long-term arsenic exposure. Hypertension. 25:53-60.
Chen GQ, S.X., Tang W. 1997. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood. 89:3345-53.
Chen, G.Q., J. Zhu, X.G. Shi, J.H. Ni, H.J. Zhong, G.Y. Si, X.L. Jin, W. Tang, X.S. Li, S.M. xong, Z.X. Shen, G.L. Sun, J. Ma, P. Zhang, T.D. Zhang, C. Gazin, T. Naoe, S.J. Chen, Z.Y. Wang, and Z. Chen. 1996. In virto studies on cellular and molecular mechanisms of arsenic trioxide(As2O3) in the treatment of acute promyelocytic leukemia:As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood. 88:1052-61.
Crecelius, E.A. 1977. Changes in the chemical speciation of arsenic following ingestion by man. Environ. Health Perspect. 19:147-150.
Cunningham, I., T.S. Gee, L.M. Reich, S.J. Kempin, A.N. Naval, and B.D. Clarkson. 1989. Acute promyelocytic leukemia: treatment results during a decade at Memorial Hospital. Blood. 73:1116-1122.
De, T.H., C. Chomienne, M. Lanotte, L. Degos, and A. Dejean. 1990. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature. 347:558-561.
Del Razo, L.M., M.A. Arellano, and M.E. Cebrian. 1990. The oxidation states of arsenic in well-water from a chronic arsenicism of Northern Mexico. Environ. Pollut. 64:143-153.
Fan, S.R., I.C. Ho, F.L. Yeoh, C.J. Lin, and T.C. Lee. 1996. Squalene inhibits sodium arsenite-induced sister chromatid exchanges and micronuclei in Chinese hamster ovary-K1 cells. Mutat. Res. 368:165-9.
Farzaneh, F., R. Meldrum, and S. Shall. 1987. Transient formation of DNA strand breaks during the induced differentiation of a human promyelocytic leukaemic cell line, HL-60. Nucleic. Acids. Res. 24:3493-3502.
Fischer, A.B., J.P. Buchet, and R. Lauwerys. 1985. Arsenic uptake, cytotoxicity and detoxification studied in mammalian cells in culture. Arch. Toxicol. 57:168-172.
Ganem, G., J. Fischer, and M. Marty. 1983. Prognostic factors in acute promyelocytic leukemia (APL): a retrospective study of 101 patients treated by daunorubicin containing remission induction regimen. Blood. 63:171-173.
Gralnick, H.R., and C. Sultan. 1975. Acute promyelocytic leukaemia: haemorrhagic manifestation and morphologic criteria. Br. J. Haematol. 29:373-376.
Gurley, L.R., R.A. Walters, J.H. Jett, and R.A. Tobey. 1980. Response of CHO cell proliferation and histone phosphorylation to sodium arsenite. J. Toxicol. Environ. Health. 6:87-105.
Huang, R.N., and T.C. Lee. 1996. Cellular uptake of trivalent arsenite and pentavalent arsenate in KB cells cultured in phosphate-free medium. Toxicol.Appl. Pharmacol. 136:243-9.
IARC. 1980. Carcinogenesis of arsenic and arsenic compounds. IARC.23:37-141.
Ishii, T., M. Yamada, H. Sato, M. Matsue, S. Taketani, K. Nakayama, Y. Sugita, and S. Bannai. 1993. Cloning and characterization of a 23-kDa stress-induced mouse peritoneal macrophage protein. J. Biol. Chem. 268:18633-18636.
Ishinishi, N., A. Yamamoto, A. Hisanaga, and T. Inamasu. 1983. Tumorigenicity of arsenic trioxide to the lung in syrian golden hamsters by intermittent instillations. Cancer Lett. 21:141-147.
Iwahara, S., H. Satoh, D.X. Song, J. Webb, A.L. Burlingame, Y. Nagae, and U. Muller-Eberhard. 1995. Purification, characterization, and cloning of a heme-binding protein (23 kDa) in rat liver cytosol. Biochemistry. 34:13398-13406.
Kantarjian, H.M., M.J. Keating, and R.S. Walters. 1986. Acute promyelocytic leukemia: M.D. Anderson Hospital experience. Am. J. Med .80:789-797.
Kawai, S., S. Takeshita, M. Okazaki, R. Kikuno, A. Kudo, and E. Amann. 1994. Cloning and characterization of OSF-3, a new member of the MER5 family, expressed in mouse osteoblastic cells. J. Biochem. 115:641-3.
Knowles, F.C., and A.A. Benson. 1983. The biochemistry of arsenic. Trends. Biochem. Sci. 8:178-180.
Kubota, T., K. Andoh, H. Sadakata, H. Tanaka, and N. Kobayashi. 1991. Tissue factor released from leukemic cells. Thromb. Haemost. 65:59-63.
Lee, T.C., and I.C. Ho. 1995. Modulation of cellular antioxidant defense activities by sodium arsenite in human fibroblasts. Arch. Toxicol. 69:498-504.
Lee, T.C., M. Oshimura, and J.C. Barrett. 1985. Comparison of arsenic-induced cell transformation, cytotoxicity, mutation and cytogenetic effects in syrian hamster embryo cells in culture. Carcinogenesis. 6:1421-1426.
Lee, T.H., S.L. Yu, S.U. Kim, Y.M. Kim, I. Choi, S.W. Kang, S.G. Rhee, and D.Y. Yu. 1999a. Characterization of the murine gene encoding 1-Cys peroxiredoxin and identification of highly homologous genes. Gene. 234:337-344.
Lee, T.H., S.L. Yu, S.U. Kim, K.K. Lee, S.G. Rhee, and D.Y. Yu. 1999b. Characterization of mouse peroxiredoxin I genomic DNA and its expression. Gene. 239:243-250.
Li, W., and I.N. Chou. 1992. Effects of sodium arsenite on the cytoskeleton and cellular glutathione levels in cultured cells. Toxicol.Appl. Pharmacol. 114:132-139.
Liu, Y.C., and H. Huang. 1997. Involvement of calcium-dependent protein kinase C in arsenite-induced genotoxicity in Chinese hamster ovary cells. J. Cell Biochem. 64:423-33.
Longo, L., P.P. Pandolfi, and A. Biondi. 1990. Rearrangements and aberrant expression of the retinoic acid receptor alpha gene in acute promyelocytic leukemias. J. Exp. Med. 172:1571-1575.
Lynn, S., J.N. Shiung, J.R. Gurr, and K.Y. Jan. 1998. Arsenite stimulates poly(ADP-ribosylation) by generation of nitric oxide. Free Radic. Biol. Med. 24:442-449.
Mann, S., P.O. Droz, and M. Vahter. 1996. Physiologically based pharmacokinetic model for arsenic exposure. II. Validation and application in humans. Toxicol.Appl. Pharmacol. 140:471-86.
Maria, K., E. Stefan, and A. Gunnar. 1996. The comet assay: mechanisms and technical consideration. Mutation Research. 363:89-96.
Marty, M., G. Ganem, and J. Fisher. 1984. Leucemie aigue promyelocytaire: etude retrospective de 119 malades traites par Daunorubicine. Nouv. Rev. Fr. Hematol. 26:371-378.
Mayer, R.J., C.A. Schiffer, and B.A. Peterson. 1987. Intensive postremission therapy in adults with acute nonlymphocytic leukemia using various dose schedules of ara-C: a progress report from the CALGB. Cancer and Leukemia Group B. Semin. Oncol. 14:251-257
Morton, W.E., and D.A. Dunnette. 1994. Arsenic in the environment, New York.
Prosperi, M.T., D. Ferbus, I. Karczinski, and G. Goubin. 1993. A human cDNA corresponding to a gene overexpressed during cell proliferation encodes a product sharing homology with amoebic and bacterial proteins. J. Biol. Chem. 268:11050-11056.
Prosperi, M.T., D. Ferbus, D. Rouillard, and G. Goubin. 1998. The pag gene product, a physiological inhibitor of c-abl tyrosine kinase, is overexpressed in cells entering S phase and by contact with agents inducing oxidative stress. FEBS Lett. 423:39-44.
Rowley, J.D., and H.M. Golomb. 1977. Dougherty 15/17 Translocation: a consistent chromosomal change in acute promyelocytic leukaemia. Lancet. 1:549-550.
Sanz, M.A., I. Jarque, and G. Martin. 1988. Acute promyelocytic leukemia: therapy results and prognostic factors. Cancer. 61:7-13.
Scheinberg, D.A., P.P. Pandolfi, and R.P. Warrell. 1998. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N. Engl. J. Med. 339:26-31.
Shau, H., L.H. Butterfield, R. Chiu, and A. Kim. 1994. Cloning and sequencing analysis of candidate human natural killer-enhancing factor genes. Immunogenetics. 40:129-134.
Sheehy, J.W., and J.H. Jones. 1993. Assessment of arsenic exposures and controls in gallium arsenide production. Am. Ind. Hyg. Assoc. J. 54:61-69.
Shen ZX, C.G., Ni JK. 1997. Use of arsenic trioxide(AS2O3) in the treatment of acute promyelocytic leukemia(APL): . Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 89:3354-60.
Stone, R.M., and R.J. Mayer. 1990. The unique aspects of acute promyelocytic leukemia. J. Clin. Oncol. 8:1913-1921.
Tseng, C.H., C.K. Chong, C.J. Chen, and T.Y. Tai. 1996. Dose-response relationship between peripheral vascular disease and ingested inorganic arsenic among residents in blackfoot disease endemic villages in Taiwan. Atherosclerosis. 120:125-33.
Vahter, M., and J. Envall. 1983. In vivo reduction of arsenate in mice and rabbits. Environ. Res. 32:14-24.
Wang, T.S., C.F. Kuo, K.Y. Jan, and H. Huang. 1996. Arsenite induces apoptosis in Chinese hamster ovary cells by generation of reactive oxygen species. J. Cell. Physiol. 169:256-68.
Wanger, J.R., and H. Huang. 1992. Active oxygen species are involved in the induction of micronuclei by arsenite in XRS-5 cells. Proc. Natl. Acad. U.S.A. 89:3380-3384.
Warrell, R.P., T.H. De, and Z.Y. Wang. 1993. Acute promyelocytic leukemia. N. Engl. J. Med. 329:177-189.
Watabe, S., H. Kohno, H. Kouyama, T. Hiroi, N. Yago, and T. Nakazawa. 1994. Purification and characterization of a substrate protein for mitochondrial ATP-dependent protease in bovine adrenal cortex. J. Biochem. 115:648-654.
Wen, S.T., and R.A. Van Etten. 1997. The pag gene product, a stress-induced protein with antioxidant properties, is an Abl SH-3 binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity. Genes. Dev. 11:2456-67.
Wen, W.N., T.L. Lieu, H.J. Chang, S.W. Wuu, M.L. Yau, and K.Y. Jan. 1981. Baseline and sodium arsenite-induced sister chromatid exchange in cultured lympocytes from patients with Blackfoot disease and healthy persons. Hum. Genet. 59:201-203.
Yamanaka, K., A. Hasegawa, R. Sawamura, and S. Okada. 1991. Cellular response to oxidative damage in lung induced by the administration of dimethylarsenic acid, a major metabolite of inorganic arsenics, in mice. Toxicol. Appl. Pharmacol. 108:205-213.
Yih, L.H., and T.C. Lee. 1999. Effects of exposure protocols on induction of kinetochore-plus and -minus micronuclei by arsenite in diploid human fibroblasts. Mutat. Res. 440:75-82.
Zhang, P., B. Liu, S.W. Kang, M.S. Seo, S.G. Rhee, and L.M. Obeid. 1997. Thioredoxin peroxidase is a novel inhibitor of apoptosis with a mechanism distinct from that of Bcl-2. J. Biol. Chem. 272:30615-18. |